Impact of stimulation of parasympathetic activity by transcutaneous auricular vagus nerve stimulation (taVNS) on quality of life (QoL) relating to digestive symptoms in patients undergoing first-line treatment for ovarian cancer, as compared to shame taVNS
Patient ≥ 18 years old
ECOG 0-2
Histologically proven epithelial ovarian carcinoma
FIGO stage ≥ IIB
Patient with an active implantable medical device or any other implanted electronic or electrical device (pacemaker, defibrillator, etc.)
Dermatological problems in the area where stimulation electrodes are applied
Recent history (<2 years) of epileptic seizures
Proven severe cardiovascular disease (such as known FEV <40%, severe valvulpathy…) or HRV analysis not possible (such as uncontrolled atrial fibrillation)